English

    The growing threat of AMR

    The world is losing its most powerful tool in healthcare: antibiotics.

    The reason: rapidly rising antibiotic-resistant infections – also called antimicrobial resistance, or AMR.

    These infections can affect anyone, of any age, in any country. AMR is a universal issue that impacts us all – we are all at risk.

    Antibiotic resistance undermines every aspect of medicine today. We rely on the availability of effective antibiotics to be able to do everything from wisdom tooth extractions to organ transplantation to cancer chemotherapy.

    The fragile antibiotic pipeline is close to collapse

    The fragile antibiotic pipeline is close to collapse

    Despite the huge societal costs of AMR, there is no viable market for new antibiotics and therefore little funding available to support clinical research.

    As a result, important antibiotics in the early stages of development may never get over the “valley of death” to reach patients.

    Read More

    Bridging the gap

    $1

    The ground-breaking AMR Action Fund expects to invest more than US$1 billion to bridge the funding gap and respond to the AMR threat.

    2-4

    The Fund aims to bring 2-4 new antibiotics to market this decade that will save patient lives.

    The concept of the AMR Action Fund was developed in collaboration with the World Health Organization, the European Investment Bank, and the Wellcome Trust. It aims to overcome key technical and funding barriers of late-stage antibiotic development and will work with governments to ensure there is a sustainable pipeline of new antibiotics to fight superbugs.

    Together, we must act now to safeguard our future from this global threat.

    Read More

    Our Investors
    Quote
    AMR is a slow tsunami that threatens to undo a century of medical progress. I very much welcome this new engagement of the private sector in the development of urgently-needed antibacterial treatments. WHO looks forward to working with the AMR Action Fund to accelerate research to address this public health crisis.
    — Dr Tedros Adhanom Ghebreyesus
    Director General, World Health Organization
    EIB is actively supporting identified market failures with innovative financial instruments, antimicrobial resistance is clearly one. We welcome the opportunity to join forces with public and private actors, such as the pharmaceutical industry, philanthropic funders, multilateral development banks, and the World Health Organization to tackle this threat. The initiative is aligned with the EIB’s core objectives in health and we are proud to be part of the origination group of the new AMR Action Fund.
    — Werner Hoyer
    President, European Investment Bank
    My 18-month-old son Simon woke up one morning screaming in agony. Within 24 hours, he died from a drug-resistant infection that doctors were powerless to stop. Had effective antibiotics been available, he would still be with us today. For the first time in years, there is real hope on the horizon. The AMR Action Fund’s investment in new antibiotics will provide funding for the sorts of lifesaving treatments that could have saved my son.
    — Everly Macario
    Public Health Advocate
    An Industry-led Fund

    An Industry-led Fund

    The pharmaceutical industry, in collaboration with the WHO, EIB, and the Wellcome Trust, came together to design the AMR Action Fund. So far, over 20 leading pharmaceutical companies, along with global philanthropies and development banks, have pledged to invest nearly US$1 billion through the new AMR Action Fund.

    The AMR Action Fund will bridge innovative candidates in the pipeline through the most challenging later stages of drug development, ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline.

    The AMR Action Fund expects to invest more than US$1 billion with the support of future partners, such as philanthropies, development banks and multilateral organizations. It will form one of the largest collective ventures ever set up to address AMR.

    Read More

    © 2021 AMR Action Fund All rights reserved. |